ctDNA-guided treatment for early rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether measuring tiny amounts of cancer DNA in the blood before standard treatment can help decide who might safely skip chemotherapy before surgery. It aims to see if a less intensive approach works as well for patients with early rectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been newly diagnosed with rectal cancer that has not spread to other parts of the body.
- You must be able to provide a blood sample for the ctDNA test.
- You must be willing to follow the study schedule and procedures.
- If you have had prior treatment for rectal cancer, you may only be eligible for one specific part of the study (the part for patients who have already received chemotherapy and radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood test that finds tumor DNA can help doctors choose the best treatment for rectal cancer, possibly allowing some patients to avoid surgery. It tests different chemotherapy and radiation combinations to see if the cancer disappears completely.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
This study looks at whether a genetic test on a small sample of your tumor can predict how well you will respond to chemotherapy and radiation before surgery. This might help doctors choose the best treatment for you.
This trial tests whether a newer approach can treat early-stage rectal cancer without removing the whole rectum, aiming to preserve bowel function. It compares different treatment options to see which is safest and most effective.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.